ArticleNature communications2016
Evolution of multiple cell clones over a 29-year period of a CLL patient.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- BAP31 Plays an Essential Role in Mouse B Cell Development via Regulation of BCR Signaling.International journal of molecular sciences · 2024Article
- Comprehensive profiling of cell subsets of gastric cancer and liver metastasis based on single cell RNA-sequencing analysis.Translational cancer research · 2024Article
- Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia.Frontiers in oncology · 2023Review
- Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features.Nature genetics · 2022Article
- Towards precision medicine in lymphoid malignancies.Journal of internal medicine · 2022Review
- scDPN for High-throughput Single-cell CNV Detection to Uncover Clonal Evolution During HCC Recurrence.Genomics, proteomics & bioinformatics · 2021Article
- Krüppel-like factor 4 promotes survival and expansion in acute myeloid leukemia cells.Oncotarget · 2021Article
- Comprehensive analysis of metastatic gastric cancer tumour cells using single-cell RNA-seq.Scientific reports · 2021Article
- Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective.Frontiers in oncology · 2021Review
- Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL.Biomarker research · 2020Article
- Clonal dynamics in chronic lymphocytic leukemia.Hematology. American Society of Hematology. Education Program · 2019Review
- Clonal dynamics in chronic lymphocytic leukemia.Blood advances · 2019Article
- Concise Review: Regulation of Self-Renewal in Normal and Malignant Hematopoietic Stem Cells by Krüppel-Like Factor 4.Stem cells translational medicine · 2019Review
- Review
- Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia.Scientific reports · 2019Article
- Combined somatic mutation and copy number analysis in the survival of familial CLL.British journal of haematology · 2018Article
- Article
- KLF4 represses MAP2K7 signaling in T-ALL.Oncotarget · 2017Article
- Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia.Oncotarget · 2017Article
- Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.Experimental hematology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 5 institutions in 3 countries.
Funding
Abstract
Chronic lymphocytic leukaemia (CLL) is a frequent B-cell malignancy, characterized by recurrent somatic chromosome alterations and a low level of point mutations. Here we present single-nucleotide polymorphism microarray analyses of a single CLL patient over 29 years of observation and treatment, and transcriptome and whole-genome sequencing at selected time points. We identify chromosome alterations 13q14-, 6q- and 12q+ in early cell clones, elimination of clonal populations following therapy, and subsequent appearance of a clone containing trisomy 12 and chromosome 10 copy-neutral loss of heterogeneity that marks a major population dominant at death. Serial single-cell RNA sequencing reveals an expression pattern with high FOS, JUN and KLF4 at disease acceleration, which resolves following therapy, but reoccurs following relapse and death. Transcriptome evolution indicates complex changes in expression occur over time. In conclusion, CLL can evolve gradually during indolent phases, and undergo rapid changes following therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.